ICU length of stay (selenium) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Length of hospital stay · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Adverse events · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Treatment failure · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes treatment failure compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Chronic lung disease · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Duration of any form of respiratory support (any form of non‐invasive respiratory support with or without supplemental oxygen) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
ICU length of stay (general intensive care patients) · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Adverse events ‐ nasal trauma · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes adverse events ‐ nasal trauma compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Adverse events ‐ abdominal overdistention · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
It is very uncertain whether summary of findings table ‐ High flow nasal cannula (HFNC) changes adverse events ‐ abdominal overdistention compared with continuous positive airway pressure (CPAP) (very low certainty).
1 finding from 1 review
Death · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
1 finding from 1 review
Treatment failure · respiratory support in term infants (infants ≥ 37 weeks gestational age to the end of the neonatal period (up to 1 month postnatal age))
Summary of findings table ‐ High flow nasal cannula (HFNC) may leads to lower treatment failure compared with low flow nasal cannula (LFNC) (low certainty).
1 finding from 1 review
Hypoglycaemia · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel leads to lower hypoglycaemia (investigator‐defined) compared with placebo (high certainty).
1 finding from 1 review
Major neurological disability at 2 years of age (Defined as any of the following: legal blindness, sensorineural deafness requiring hearing aids, moderate or severe cerebral palsy or developmental delay/intellectual impairment (developmental quoti... · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in major neurological disability at 2 years of age (Defined as any of… compared with placebo (low certainty).
1 finding from 1 review
Receipt of treatment for hypoglycaemia during initial hospital stay (investigator‐defined, any treatment ‐ oral dextrose gel, intravenous dextrose, or other drug therapy) during initial hospital stay (yes/no) · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in receipt of treatment for hypoglycaemia during initial hospital stay… compared with placebo (moderate certainty).
1 finding from 1 review
Receipt of intravenous treatment for hypoglycaemia (yes/no) · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in receipt of intravenous treatment for hypoglycaemia (yes/no) compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events# (e.g. choking or vomiting at time of administration) · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in adverse events# (e.g. choking or vomiting at time of administration) compared with placebo (moderate certainty).
1 finding from 1 review
Separation from mother for treatment of hypoglycaemia · newborn infants at risk of neonatal hypoglycaemia
Dextrose gel showed no clear difference in separation from mother for treatment of hypoglycaemia (infant nursed… compared with placebo (low certainty).
1 finding from 1 review
Breastfeeding (exclusive after discharge) ‐ not reported (WHO 2008 definition (yes/no)) · newborn infants at risk of neonatal hypoglycaemia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality Mortality at latest · preterm or low birth weight infants
Early (less than seven days following birth) higher showed no clear difference in mortality (latest time reported up to hospital discharge) compared with lower sodium intake (low certainty).
1 finding from 1 review
Hyponatraemia (< 130 mmol/L) · preterm or low birth weight infants
Late (seven days or more following birth) higher may leads to lower hyponatraemia (< 130 mmol/L) compared with lower sodium intake (low certainty).
1 finding from 1 review